Goldenwell Biotech, Inc. (GWLL)

Market Cap	19.80M
Revenue (ttm)	139.00
Net Income (ttm)	-134.82K
Shares Out	99.00M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,500
Average Volume	5,140
Open	0.2000
Previous Close	0.2000
Day's Range	0.2000 - 0.2000
52-Week Range	0.2000 - 0.3275
Beta	2.15
RSI	n/a
Earnings Date	Aug 26, 2025

About Goldenwell Biotech

Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2019
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: GWLL

Financial Performance

In 2024, Goldenwell Biotech's revenue was $139, a decrease of -92.43% compared to the previous year's $1,836. Losses were -$131,498, 12.0% more than in 2023.